Skip to main content

The neurologist December 2006, Volume 77, Issue 12, pp 1501-1505 | Cite as Acute intermittent porphyria A clinical chameleon: Case report of a 40-year-old female patient

The neurologist

December 2006, Volume 77, Issue 12, pp 1501-1505 | Cite as

Acute intermittent porphyria
A clinical chameleon: Case report of a 40-year-old female patient
Authors and affiliations
M. ZimmermannEmail authorC. BonaccursoC. ValeriusG.F. Hamann
Case reports
Acute porphyrias, although rare, often lead to misdiagnosed and dramatic clinical pictures. Various clinical pictures can be mimicked by the combination of internal, psychiatric and neurological symptoms. The report is about a 40-year-old female patient presented with a subacute tetraparesis in our clinic. In the previous months, the patient had been treated several times for abdominal symptoms in a medical and later on because of delirious symptoms with hallucinations in a psychiatric hospital. The typical triad of motor axonal neuropathy, abdominal discomfort, and psychiatric symptoms quickly led to the diagnosis of acute intermittent porphyria by determining urinary metabolites of porphyrin. The prognosis of acute porphyrias has improved significantly with insights into the pathogenesis of these diseases. The determination of the enzyme activities of the porphyrin metabolism also enables a diagnosis at the symptom-free interval. In the case of a positive family history, molecular genetic mutation screening may identify asymptomatic family members at increased risk of developing porphyria.

Acute porphyrias Axonal neuropathy Heme synthesis Molecular genetic mutation screening
Acute intermittent porphyria
A clinical chameleon: case study of a 40-year-old female patient
Acute porphyrias are rare, but often misdiagnosed and may take a dramatic clinical course. The combination of various internal, psychiatrical and neurological symptoms can mimic different other diseases. We report a 40-year-old female patient who was admitted with a subacute tetraparesis. During the last two months the patient was treated for acute mental changes and hallucinations. The typical combination of abdominal pain, motor neuropathy and psychiatric symptoms confirmed by increased amounts of porphyrins and their precursors, led us to promptly diagnose acute intermittent porphyria. Better knowledge about the pathogenesis has clearly improved the prognosis of acute porphyria. In remission, measurement of enzyme activities or mutation screening can only be performed. A mutation screening for family members should be conducted to identify symptom-free carriers, especially in cases of a positive family history.


  1. 1.
    Anderson KE, Spitz IM, Bardin CW, Kappas A (1990) A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria. Arch Intern Med 150: 1469–1474CrossRefPubMedGoogle Scholar
  2. 2.
    Crimlisk HL (1997) The little imitator-porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry 62: 319–328PubMedGoogle Scholar
  3. 3.
    Dichter HN, Taddeini L, Lin S, Ayala GF (1977) Delta amino levulinic acid. Effect of a porphyrin precursor on an isolated neuronal preparation. Brain Res 126: 189–195CrossRefPubMedGoogle Scholar
  4. 4.
    Doss MO, Kuhnel A, Gross U (2000) Alcohol and porphyrin metabolism. Alcohol Alcohol 35: 109–125PubMedGoogle Scholar
  5. 5.
    Gordon N (1999) The acute porphyrias. Brain Dev 21: 373–377CrossRefPubMedGoogle Scholar
  6. 6.
    Gross U, Honcamp M, Daume E et al. (1995) Hormonal oral contraceptives, urinary porphyrin excretion and porphyrias. Horm Metab Res 27(8): 379–383PubMedGoogle Scholar
  7. 7.
    Kauppinen R (2005) Porphyrias. Lancet 365: 241–252PubMedGoogle Scholar
  8. 8.
    Kremer GJ (1994) Hepatische Porphyrien. In: Weihrauch W (Hrsg) Internistische Therapie 1994/1995, 10. Aufl. Urban & Schwarzenberg, München, S 964–968Google Scholar
  9. 9.
    Lindberg RL, Martini R, Baumgartner M et al. (1999) Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J Clin Invest 103(8): 1127–1134PubMedGoogle Scholar
  10. 10.
    Meyer UA, Schuurmans MM, Lindberg RL (1998) Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis 18(1): 43–52PubMedGoogle Scholar
  11. 11.
    Pischik E, Bulyanitsa A, Kazakov V, Kaupinnen R (2004) Clinical features predictive of a poor prognosis in acute porphyria. J Neurol 251(12): 1538–1541CrossRefPubMedGoogle Scholar
  12. 12.
    Sommer N, Gleichmann M (2003) Polyneuropathien. In: Brandt T, Dichgans J, Diener HC (Hrsg) Therapie und Verlauf neurologischer Erkrankungen, 4. Aufl. Kohlhammer, Stuttgart, S 1203–1217Google Scholar
  13. 13.
    Soonawalla ZF, Orug T, Badminton MN et al. (2004) Liver transplantation as a cure for acute intermittent porphyria. Lancet 363: 705–706CrossRefPubMedGoogle Scholar
  14. 14.
    Yen PS; Chen CJ, Lui CC et al. (2002) Diffusion-weighted magnetic imaging of porphyric encephalopathy: a case report. Eur Neurol 48: 119–121CrossRefPubMedoogle Scholar


Popular posts from this blog

Amazing patient advocacy....and needed media for this issue. Thank you Terri Witter!


What could it be?
Nerve Pain WHAT IS NEUROPATHIC PAIN? Neuropathic or nerve pain (NP) is a long-term or chronic pain disease that results from nerve damage. It can be caused by different diseases or conditions. Worldwide nerve pain affects as many as 26 million people. Neuropathic or nerve pain may affect larger areas of the body or it can be restricted to a smaller area, in this case it is called localized neuropathic pain (LNP). WHAT CAUSES NEUROPATHIC PAIN? Neuropathic or nerve pain may occur in the absence of an obvious visible cause (e.g. an accident, an injury, a chemical burn). There are several external situations that can directly damage nerves and lead to neuropathic pain, such as: Amputation of a limb (phantom pain, stump pain)Surgery (scar pain, post-surgery pain)Trauma or accident Neuropathic pain is also a common complication of other diseases, including nerve damage after shingles or herpes zoster infection (postherpetic neuralgia or PHN), nerve damage after HIV infectio…


GLOBAL PORPHYRIA ALLIANCE The APF is proud to support our members that live across the globe. Many countries around the world have developed organizations to support their local communities. We hope that enjoy the same opportunity to communicate with one another, develop friendships, and learn about porphyria. Here are links to patient advocacy groups worldwide that offer support to individuals impacted by porphyria. Argentina: Centro de investigaciones sobre porfirinas y porfirias | More informationAustralia: Porphyria Association, Inc. | More informationBrazil: Associação Brasileira de Porfiria | More informationCanada: Canadian Association for Porphyria | More informationColombia: Fundación Colombiana Para La Porfiria | More informationDenmark: (Porphyria Association Denmark)Denmark: (Danish Porphyria Support Group)England: British Porphyria AssociationFinland: Finnish Porphyria Support Group France: Association Française des Malades Atteints de Por…